- Home
- CLPR vs BTAI Comparison
CLPR vs BTAI Comparison
Compare CLPR & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | BTAI |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 49.2M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CLPR | BTAI |
|---|---|---|
| Price | $3.45 | $1.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 70.1K | ★ 578.0K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | ★ 11.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,179,000.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $416.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.90 | N/A |
| 52 Week Low | $3.37 | $1.17 |
| 52 Week High | $6.49 | $9.26 |
Technical Indicators
Market Signals| Indicator | CLPR | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 41.85 | 44.03 |
| Support Level | $3.39 | $1.82 |
| Resistance Level | $3.50 | $2.30 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 19.05 | 11.78 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.